Successful treatment with crizotinib after alectinib-induced interstitial lung disease

Although alectinib is a well-tolerated and highly effective inhibitor of a second-generation anaplastic lymphoma kinase, special attention should be paid to the possibility of potentially severe and fatal adverse events such as interstitial pneumonia. We report a case of a patient with advanced non-...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Ning, Lin, Shanhong, He, Lei, Wang, Linfeng, Kong, Weiliang, Cao, Chao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411646/
https://www.ncbi.nlm.nih.gov/pubmed/34484794
http://dx.doi.org/10.1177/2050313X211042991

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411646/
https://www.ncbi.nlm.nih.gov/pubmed/34484794
http://dx.doi.org/10.1177/2050313X211042991

Ejemplares similares